Incyte Corporation (INCY) on Decifer

Decifer ranks INCY number 7 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 21% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 21% a year, profits grew 4,019% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares.
• One customer accounts for about 21% of revenue, a real risk if that relationship changes.
• A specialty-drug franchise owner with returns around 21%, profits up 4019%, and momentum of 17 out of 35 still only partly recognized inside a funded worldview.

The current read

The evidence on INCY lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full INCY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.